Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Study Details
Study Description
Brief Summary
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Hematologists
|
Behavioral: Hematolo-GIST Training
Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
|
| Patients
|
Behavioral: Participants Appointment
Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
|
Outcome Measures
Primary Outcome Measures
- Feasibility of the Hematolo-GIST intervention among hematologists and participants [Up to 1 year]
Feasbility is defined as ≥70% of screened eligible hematologists and participants enrolling in the study and ≥80% of hematologists learning the approach
Eligibility Criteria
Criteria
Inclusion Criteria:
Hematologists
- Currently a hemotologic oncologist providing care to patients with DLBCL
Patients
-
Per medical record, is being treated by a hematologic oncologist participating in this study
-
Per medical record, has a diagnosis of DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
-
Per medical record, receipt of ≥ 4 cycles of first-line therapy or 2 cycles of later-line therapy as best response to chemotherapy or relapse ≤ 12 months after autologous stem cell transplant (ACST)
-
Per medical record, received an anti-CD20 monoclonal antibody or an anthracycline as one of their qualifying regiments
-
Self-identify as Black and/or White
-
Per medical record, 18 years of age or older
-
Per self-report, fluent in English** ** Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
-
How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
-
What is your preferred language for healthcare? (must respond English)
Exclusion Criteria:
Hematologists
- Per self-report, planning to leave the cancer center in the next 12 months
Patients
-
Moderately or severely cognitively impaired as demonstrated by Short Portable Mental Status Questionnaire score > 4
-
Per research staff judgment and/or self-report, too ill or weak to complete study procedures
-
Per medical record or self-report, receiving hospice care at the time of enrollment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Memorial Sloan Kettering Cancer Center (All protocol activities) | New York | New York | United States | 10065 |
| 2 | NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only) | New York | New York | United States | 10065 |
| 3 | Weill Cornell Medical College (Data analysis only) | New York | New York | United States | 10065 |
Sponsors and Collaborators
- Memorial Sloan Kettering Cancer Center
Investigators
- Principal Investigator: Kelly McConnell, PhD, Memorial Sloan Kettering Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 23-164